Emboldened by a positive PhIII, Novartis steers a late-stage BTK inhibitor into a pivotal MS trial
Novartis is taking a digital turn at the upcoming ECTRIMS conference with dozens of abstracts on its immunology drugs already on the market. And notably, the pharma giant is using the occasion to announce that its oral BTK inhibitor remibrutinib is being steered into a late-stage study on multiple sclerosis — pitting them against some heavyweight rivals.
The announcement comes just a week after the Swiss pharma giant boasted about their drug’s success against chronic spontaneous urticaria, which triggers painful swelling, in a Phase IIb trial. And after considerable speculation in the field, Novartis believes it has another “best in class” contender for blockbuster status in MS.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.